Growth Metrics

Fulgent Genetics (FLGT) Net Cash Flow (2016 - 2026)

Fulgent Genetics' Net Cash Flow history spans 12 years, with the latest figure at -$26.8 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 320.99% to -$26.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$44.0 million, a 445.91% decrease, with the full-year FY2025 number at -$5.1 million, up 88.0% from a year prior.
  • Net Cash Flow hit -$26.8 million in Q1 2026 for Fulgent Genetics, up from -$67.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for FLGT hit a ceiling of $188.2 million in Q1 2022 and a floor of -$213.7 million in Q2 2022.
  • Historically, Net Cash Flow has averaged -$8.3 million across 5 years, with a median of -$2.8 million in 2024.
  • The widest YoY moves for Net Cash Flow: up 519.49% in 2025, down 2342.95% in 2025.
  • Tracing FLGT's Net Cash Flow over 5 years: stood at -$89.0 million in 2022, then surged by 114.89% to $13.3 million in 2023, then plummeted by 120.86% to -$2.8 million in 2024, then tumbled by 2342.95% to -$67.5 million in 2025, then soared by 60.31% to -$26.8 million in 2026.
  • Business Quant data shows Net Cash Flow for FLGT at -$26.8 million in Q1 2026, -$67.5 million in Q4 2025, and $29.7 million in Q3 2025.